The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.

Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, Boccia S, Castillo-Polo JA, Magrini E, Garcia-Vello P, Wool E, Gigante V, Duffy E, Cassini A, Huttner B, Pardo PR, Naghavi M, Mirzayev F, Zignol M, Cameron A, Tacconelli E, WHO Bacterial Priority Pathogens List Advisory Group. · 2025

Read The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. by Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, Boccia S, Castillo-Polo JA, Magrini E, Garcia-Vello P, Wool E, Gigante V, Duffy E, Cassini A, Huttner B, Pardo PR, Naghavi M, Mirzayev F, Zignol M, Cameron A, Tacconelli E, WHO Bacterial Priority Pathogens List Advisory Group. (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc12367593.txt.

Introduction

Sati and colleagues updated the WHO priority list for drug-resistant bacteria in 2025. The World Health Organization first issued the list in 2017. It steers policy, research money, and drug development. At least 13 new antibiotics had since gained approval.

The 2024 list scores 24 resistant pathogens on eight criteria. Criteria include deaths, illness burden, and spread trends. A structured decision method weighed expert input. The update fixes limits seen in the first list. Sati aims global effort at the most urgent threats. Antibiotic resistance keeps growing, so priorities need refresh. The list sorts pathogens into critical, high, and medium tiers. Gram-negative bacteria top the critical tier.

Catalog record

CREATORSati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, Boccia S, Castillo-Polo JA, Magrini E, Garcia-Vello P, Wool E, Gigante V, Duffy E, Cassini A, Huttner B, Pardo PR, Naghavi M, Mirzayev F, Zignol M, Cameron A, Tacconelli E, WHO Bacterial Priority Pathogens List Advisory Group.
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12367593

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance By Hatim Sati, Elena Carrara, Alessia Savoldi, Paul Hansen, Jacopo Garlasco, Enrica Campagnaro, Simone Boccia, Juan Antonio Castillo-Polo, Eugenia Magrini, Pilar Garcia-Vello, Eve Wool, Valeria Gigante Published in: The Lancet. Infectious Diseases DOI: 10.1016/S1473-3099(25)00118-5 ABSTRACT Summary Background The 2017 WHO Bacterial Priority Pathogens List (BPPL) has been instrumental in guiding global policy, research and development, and investments to address the most urgent threats from antibiotic-resistant pathogens, and it is a key public health tool for the prevention and control of antimicrobial resistance (AMR). Since its release, at least 13 new antibiotics targeting bacterial priority pathogens have been approved. The 2024 WHO BPPL aims to refine and build on the previous list by incorporating new data and evidence, addressing previous limitations, and improving pathogen prioritisation to better guide global efforts in combating AMR. Methods The 2024 WHO BPPL followed a similar approach to the first prioritisation exercise, using a multicriteria decision analysis framework. 24 antibiotic-resistant bacterial pathogens were scored based on eight criteria, including mortality, non-fatal burden, incidence, 10-year resistance trends, preventability, transmissibility, treatability, and antibacterial pipeline status. Pathogens were assessed on each of the criteria on the basis of available evidence and expert judgement. A preferences survey using a pairwise comparison was administered to 100 international experts (among whom 79 responded and 78 completed the survey) to determine the relative weights of the criteria. Applying these weights, the final ranking of pathogens was determined by calculating a total score in the range of 0–100% for each pathogen. Subgroup and sensitivity analyses were conducted to assess the impact of experts’ consistency, background, and geographical origin on the stability of the rankings. An independent advisory group reviewed the final list, and pathogens were subsequently streamlined and grouped into three priority tiers based on a quartile scoring system: critical (highest quartile), high (middle quartiles), and medium (lowest quartile). Findings The pathogens’ total scores ranged from 84% for the top-ranked bacterium (carbapenem-resistant Klebsiella pneumoniae) to 28% for the bottom-ranked bacterium (penicillin-resistant group B streptococci). Antibiotic-resistant Gram-negative bacteria (including K pneumoniae, Acinetobacter spp, and Escherichia coli), as well as rifampicin-resistant Mycobacterium tuberculosis, were ranked in the highest quartile. Among the bacteria commonly responsible for community-acquired infections, the highest rankings were for fluoroquinolone-resistant Salmonella enterica serotype Typhi (72%), Shigella spp (70%), and Neisseria gonorrhoeae (64%). Other important pathogens on the list include Pseudomonas aeruginosa and Staphylococcus aureus. The results of the preferences survey showed a strong inter-rater agreement, with Spearman's rank correlation coefficient and Kendall's coefficient of concordance both at 0·9. The final ranking showed high stability, with clustering of the pathogens based on experts’ backgrounds and origins not resulting in any substantial changes to the ranking. Interpretation The 2024 WHO BPPL is a key tool for prioritising research and development investments and informing global public health policies to combat AMR. Gram-negative bacteria and rifampicin-resistant M tuberculosis remain critical priority pathogens, underscoring their persistent threat and the limitations of the current antibacterial pipeline. Focused efforts and sustained investments in novel antibacterials are needed to address AMR priority pathogens, which include high-burden antibiotic-resistant bacteria such as Salmonella and Shigella spp, N gonorrhoeae, and S aureus. Beyond research and development, efforts to address these pathogens should also include expanding equitable access to existing drugs, enhancing vaccine coverage, and strengthening infection prevention and control measures. Funding This work is based on the development of the 2024 WHO BPPL, which was conducted by the WHO AMR Division through grants from the Government of Austria, the Government of Germany, the Government of Saudi Arabia, and the European Commission's Health Emergency Preparedness and Response Authority. Translations For the Arabic, French, Italian, Japanese and Spanish translations of the abstract see Supplementary Materials section. INTRODUCTION The emergence and spread of antimicrobial resistance (AMR) threaten the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi.1, 2 Among all AMR pathogens, antibiotic-resistant pathogens are associated with the highest burden and health-care costs.3 In 2019, antibiotic-resistant infections caused an estimated 1·27 million deaths (95% CI 0·86–1·91) globally, disproportionately affecting low-income and middle-income countries.3 A systematic analysis estimated that 4·71 million deaths (95% uncertainty interval 4·23–5·19) were associated with bacterial AMR in 2021, including 1·14 million deaths (1·00–1·28) attributable to bacterial AMR.4 In response to the AMR threat, WHO introduced the Global Action Plan on Antimicrobial Resistance in 2015.5 Subsequently WHO launched its first Bacterial Priority Pathogens List (BPPL) in 2017,6 which had the aim of guiding the research and development of new antibacterials and was established based on pathogen resistance profiles, public health impact, and the need for new treatments. This list featured 25 antibiotic-resistant pathogens streamlined into 13 families across three priority tiers: critical, high, and medium.6, 7 Since its development, the WHO BPPL has directed research and development efforts toward pressing AMR challenges,8 and has guided AMR surveillance and other prevention and control efforts.9, 10 Research in context Evidence before this study Antimicrobial resistance (AMR), largely fuelled by antibiotic resistance, is an escalating global health threat. WHO has long recognised this challenge, notably through the 2015 WHO Global Action Plan on Antimicrobial Resistance and the development of the 2017 WHO Bacterial Priority Pathogens List (BPPL), which has since provided a key framework for guiding research and development, AMR surveillance, and public health strategies. Since the release of the 2017 BPPL, 13 new antibiotics have been authorised. However, AMR continues to emerge, with many pathogens now showing resistance to most newer antibiotics. As AMR evolves, so too must global understanding and priorities. Since 2017, new evidence and data have become available, deepening our knowledge of AMR trends and the shifting landscape of resistance. This ongoing progression necessitates an update to the original BPPL to better address the current challenges posed by resistant bacteria. This study presents the updated 2024 WHO BPPL, which addresses limitations of the 2017 WHO BPPL and incorporates the latest global data on AMR. To understand the existing evidence before this study and inform this update, we conducted a targeted literature search of PubMed and Google Scholar for studies published between Jan 1, 2017, and Nov 30, 2022, using the following search terms: “priority list AND infections”, “priority list AND resistance”, and “R&D AND priority AND bacteria”, combined with “antibiotic AND priority AND infections OR bacteria”. No limitations were placed on the type of publication or language. This search identified seven relevant publications, including the 2017 WHO BPPL report, a systematic analysis of the global burden of bacterial AMR infections in 2019, and five national priority pathogen lists. These publications informed the preliminary selection of bacterial pathogens for this prioritisation study. Added value of this study Building on the methodology and data used in the development of the 2017 WHO BPPL, the 2024 WHO BPPL introduces substantial revisions, leveraging more robust quantitative data to evaluate pathogens based on disease burden, resistance trends, and public health impact. It also incorporates qualitative criteria, such as preventability, transmission dynamics, and treatability, emphasising disparities in pathogen burden and access to treatment between high-income countries and low-income and middle-income countries. Compared with the 2017 iteration, the list introduces additional

Read the complete text